[go: up one dir, main page]

TW200509922A - Methods of therapeutic treatment using amounts of retinoid components - Google Patents

Methods of therapeutic treatment using amounts of retinoid components

Info

Publication number
TW200509922A
TW200509922A TW093122946A TW93122946A TW200509922A TW 200509922 A TW200509922 A TW 200509922A TW 093122946 A TW093122946 A TW 093122946A TW 93122946 A TW93122946 A TW 93122946A TW 200509922 A TW200509922 A TW 200509922A
Authority
TW
Taiwan
Prior art keywords
methods
amounts
therapeutic treatment
retinoid components
components
Prior art date
Application number
TW093122946A
Other languages
English (en)
Inventor
John Sefton
John R Gibson
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of TW200509922A publication Critical patent/TW200509922A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW093122946A 2003-07-30 2004-07-30 Methods of therapeutic treatment using amounts of retinoid components TW200509922A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49114303P 2003-07-30 2003-07-30

Publications (1)

Publication Number Publication Date
TW200509922A true TW200509922A (en) 2005-03-16

Family

ID=34115472

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093122946A TW200509922A (en) 2003-07-30 2004-07-30 Methods of therapeutic treatment using amounts of retinoid components

Country Status (7)

Country Link
US (1) US20050026958A1 (zh)
EP (1) EP1653941A1 (zh)
AR (1) AR045177A1 (zh)
AU (1) AU2004261286A1 (zh)
CA (1) CA2534005A1 (zh)
TW (1) TW200509922A (zh)
WO (1) WO2005011667A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060620A1 (en) * 2005-09-09 2007-03-15 John Sefton Use of RAR retinoid agonists to increase sperm count and sperm mobility in males
WO2007065289A2 (en) * 2005-12-09 2007-06-14 Basilea Pharmaceutica Ag 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322438A (en) * 1979-08-06 1982-03-30 United States Of America Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne
US5089509A (en) * 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system

Also Published As

Publication number Publication date
AR045177A1 (es) 2005-10-19
AU2004261286A1 (en) 2005-02-10
CA2534005A1 (en) 2005-02-10
US20050026958A1 (en) 2005-02-03
WO2005011667A1 (en) 2005-02-10
EP1653941A1 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
MXPA04003666A (es) Uso de flibanserina para tratamiento de trastornos sexuales.
AU2003249356A1 (en) Safe and effective nutritional supplement formulatins and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
EP1363632A4 (en) SELECTIVE CANNABIMIMETIC AMINOALKYLINDOLES OF A RECEPTOR
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
WO2006113802A3 (en) Device for administering electrode stimulation of back and abdominal muscles
AU2003264282A1 (en) Phenethanolamine derivatives and their use in the treatment of respiratory diseases
CY1109229T1 (el) Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
PT998287E (pt) Utilizacao de levobupivacaina
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
BRPI0418157A (pt) terapêutica de tumores alogênicos
AU2003272317A1 (en) Treatment of periodontal disease with photosensitizers
EP1636160A4 (en) NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLISM AND SKIN DISEASES
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
IL166016A0 (en) Topical treatment of skin diseases
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
ATE447426T1 (de) Elektromagnetische stimulation bei patienten mit osteoporose
AR052152A1 (es) Producto farmaceutico para el tratamiento preventivo y terapeutico de trastornos del sueno
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice